Anderson-Fabry disease: A cardiomyopathy that can be cured

Hellenic Journal of Cardiology

Volumn 52, Issue 4, 2011, Pages 316-326

  Anastasakis, Aris ^a   Sevdalis, Elias ^a   Papatheodorou, Efstathios ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Anderson Fabry disease; Enzyme replacement therapy; Fabry; Hypertrophic cardiomyopathy

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AMNESIA; ATAXIA; CARDIOMYOPATHY; DEFIBRILLATOR; DIPLOPIA; DIZZINESS; DYSARTHRIA; ELECTROCARDIOGRAPHY; ENZYME ACTIVITY; ENZYME REPLACEMENT; FABRY DISEASE; GENE MUTATION; GENE THERAPY; GENETIC SCREENING; HAND PARESTHESIA; HEARING LOSS; HEART ARRHYTHMIA; HEART ATRIOVENTRICULAR NODE; HEART DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HEART MUSCLE BIOPSY; HEART MUSCLE FIBROSIS; HEART MUSCLE NECROSIS; HEART VENTRICLE HYPERTROPHY; HEMANGIOKERATOMA; HEMIPARESIS; HUMAN; INCIDENCE; MICROALBUMINURIA; NONHUMAN; NYSTAGMUS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHENOTYPE; PROTEINURIA; REVIEW; SODIUM INTAKE; TINNITUS; TRANSIENT ISCHEMIC ATTACK; ULTRASOUND; VERTIGO;

DECISION TREES; FABRY DISEASE; HEART DISEASES; HUMANS;

EID: 79961150434     PISSN: 10117970     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Desnick RJ, Ioannou YA, Eng CM. a-galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular Bases of inherited disease. 8th ed. Vol 3. New York: McGraw-Hill, 2001: p. 3733-3774.
2. Peters FP, Vermeulen A, Kho TL. Anderson-Fabry's disease: alpha-galactosidase deficiency. Lancet. 2001; 357: 138-140.
3. DeGraba T, Azhar S, Dignat-George F, et al. Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol. 2000; 47: 229-233.
4. Hwu WL, Chien YH, Lee NC, et al. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A). Hum Mutat. 2009; 30: 1397-1405.
5. Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet. 2006; 79: 31-40.
6. Elleder M, Bradová V, Smíd F, et al. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol. 1990; 417: 449-455.
7. von Scheidt W, Eng CM, Fitzmaurice TF, et al. An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med. 1991; 324: 395-399.
8. Linhart A, Elliott PM. The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart. 2007; 93: 528-535.
9. Barbey F, Brakch N, Linhart A, et al. Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition. Arterioscler Thromb Vasc Biol. 2006; 26: 839-844.
10. Aerts JM, Groener JE, Kuiper S, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A. 2008; 105: 2812-2817.
11. Shen JS, Meng XL, Moore DF, et al. Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab. 2008; 95: 163-168.
12. Jung WI, Sieverding L, Breuer J, et al. 31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 1998; 97: 2536-2542.
13. Lücke T, Höppner W, Schmidt E, Illsinger S, Das AM. Fabry disease: reduced activities of respiratory chain enzymes with decreased levels of energy-rich phosphates in fibroblasts. Mol Genet Metab. 2004; 82: 93-97.
14. Morgan SH, Crawfurd MA. Anderson-Fabry disease. BMJ. 1988; 297: 872-873.
15. Grünfeld JP, Lidove O, Joly D, Barbey F Renal disease in Fabry patients. J Inherit Metab Dis. 2001; 24 Suppl 2: 71-74.
16. Mitsias P, Levine SR. Cerebrovascular complications of Fabry's disease. Ann Neurol. 1996; 40: 8-17.
17. Linhart A, Kampmann C, Zamorano JL, et al. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J. 2007; 28: 1228-1235.
18. Linhart A, Lubanda JC, Palecek T, et al. Cardiac manifestations in Fabry disease. J Inherit Metab Dis. 2001; 24 Suppl 2: 75-83.
19. Linhart A, Palecek T, Bultas J, et al. New insights in cardiac structural changes in patients with Fabry's disease. Am Heart J. 2000; 139: 1101-1108.
20. Weidemann F, Breunig F, Beer M, et al. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J. 2005; 26: 1221-1227.
21. Strotmann J, Weidemann F, Breunig F, Knoll A, Wanner C, Ertl G. Morbus Fabry of the heart. Why should cardiologists care? Z Kardiol. 2005; 94: 557-563.
22. Kampmann C, Linhart A, Baehner F, et al. Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol. 2008; 130: 367-373.
23. Kalliokoski RJ, Kalliokoski KK, Sundell J, et al. Impaired myocardial perfusion reserve but preserved peripheral endothelial function in patients with Fabry disease. J Inherit Metab Dis. 2005; 28: 563-573.
24. Elliott PM, Kindler H, Shah JS, et al. Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart. 2006; 92: 357-360.
25. Takenaka T, Teraguchi H, Yoshida A, et al. Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. J Cardiol. 2008; 51: 50-59.
26. Shah JS, Hughes DA, Sachdev B, et al. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol. 2005; 96: 842-846.
27. Keren A, Syrris P, McKenna WJ. Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression. Nat Clin Pract Cardiovasc Med. 2008; 5: 158-168.
28. Kampmann C, Wiethoff CM, Martin C, et al. Electrocardiographic signs of hypertrophy in fabry disease-associated hypertrophic cardiomyopathy. Acta Paediatr Suppl. 2002; 91: 21-27.
29. Nakao S, Takenaka T, Maeda M, et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med. 1995; 333: 288-293.
30. Ogawa K, Sugamata K, Funamoto N, et al. Restricted accumulation of globotriaosylceramide in the hearts of atypical cases of Fabry's disease. Hum Pathol. 1990; 21: 1067-1073.
31. Nagao Y, Nakashima H, Fukuhara Y, et al. Hypertrophic cardiomyopathy in late-onset variant of Fabry disease with high residual activity of alpha-galactosidase A. Clin Genet. 1991; 39: 233-237.
32. Frustaci A, Chimenti C, Ricci R, et al. Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N Engl J Med. 2001; 345: 25-32.
33. Eng CM, Fletcher J, Wilcox WR, et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis. 2007; 30: 184-192.
34. Jastrzebski M, Bacior B, Dimitrow PP, Kawecka-Jaszcz K. Electrophysiological study in a patient with Fabry disease and a short PQ interval. Europace. 2006; 8: 1045-1047.
35. Maron BJ, Gottdiener JS, Epstein SE. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a wide angle two-dimensional echocardiographic study of 125 patients. Am J Cardiol. 1981; 48: 418-428.
36. Pieroni M, Chimenti C, Ricci R, Sale P, Russo MA, Frustaci A. Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation. 2003; 107: 1978-1984.
37. Toro R, Perez-Isla L, Doxastaquis G, et al. Clinical usefulness of tissue Doppler imaging in predicting preclinical Fabry cardiomyopathy. Int J Cardiol. 2009; 132: 38-44.
38. Weidemann F, Niemann M, Herrmann S, et al. A new echocardiographic approach for the detection of non-ischaemic fibrosis in hypertrophic myocardium. Eur Heart J. 2007; 28: 3020-3026.
39. De Cobelli F, Esposito A, Belloni E, et al. Delayed-enhanced cardiac MRI for differentiation of Fabry's disease from symmetric hypertrophic cardiomyopathy. AJR Am J Roentgenol. 2009; 192: W97-102.
40. Weidemann F, Breunig F, Beer M, et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation. 2003; 108: 1299-1301.
41. Froissart R, Guffon N, Vanier MT, Desnick RJ, Maire I. Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma. Mol Genet Metab. 2003; 80: 307-314.
42. Chimenti C, Pieroni M, Morgante E, et al. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation. 2004; 110: 1047-1053.
43. Koitabashi, Nutsugi, Seki et al. Biopsy-proven cardiomyopathy in heterozygous Fabry's disease. Jpn Circ J. 1999; 63: 572-575.
44. Eng CM, Resnick-Silverman LA, Niehaus DJ, Astrin KH, Desnick RJ. Nature and frequency of mutations in the alphagalactosidase A gene that cause Fabry disease. Am J Hum Genet. 1993; 53: 1186-1197.
45. Davies JP, Winchester BG, Malcolm S. Mutation analysis in patients with the typical form of Anderson-Fabry disease. Hum Mol Genet. 1993; 2: 1051-1053.
46. Monserrat L, Gimeno-Blanes JR, Marín F, et al. Prevalence of Fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2007; 50: 2399-2403.
47. Merta M, Reiterova J, Ledvinova J, et al. A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population. Nephrol Dial Transplant. 2007; 22: 179-186.
48. Laney DA, Fernhoff PM. Diagnosis of Fabry disease via analysis of family history. J Genet Couns. 2008; 17: 79-83.
49. Rozenfeld PA, Tarabuso A, Ebner R, Ramallo G, Fossati CA. A successful approach for the detection of Fabry patients in Argentina. Clin Genet. 2006; 69: 344-348.
50. Anastasakis A, Sharma S, McKenna W. Hypertrophic cardiomyopathy. In: Toutouzas P, Stefanadis C, Boudoulas H, editors. Cardiology textbook. 2001.
51. Cantor WJ, Butany J, Iwanochko M, Liu P. Restrictive cardiomyopathy secondary to Fabry's disease. Circulation. 1998; 98: 1457-1459.
52. Sachdev B, Takenaka T, Teraguchi H, et al. Prevalence of Anderson- Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation. 2002; 105: 1407-1411.
53. Ommen SR, Nishimura RA, Edwards WD. Fabry disease: a mimic for obstructive hypertrophic cardiomyopathy? Heart. 2003; 89: 929-930.
54. Vedder AC, Linthorst GE, Houge G, et al. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS One. 2007; 2: e598.
55. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med. 2001; 345: 9-16.
56. Hughes DA, Elliott PM, Shah J, et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart. 2008; 94: 153-158.
57. Bierer G, Balfe D, Wilcox WR, Mosenifar Z. Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease. J Inherit Metab Dis. 2006; 29: 572-579.
58. Pisani A, Spinelli L, Sabbatini M, et al. Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement. Am J Kidney Dis. 2005; 46: 120-127.
59. Breunig F, Weidemann F, Strotmann J, Knoll A, Wanner C. Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int. 2006; 69: 1216-1221.
60. Kalliokoski RJ, Kantola I, Kalliokoski KK, et al. The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease. J Inherit Metab Dis. 2006; 29: 112-118.
61. Mehta A, Beck M, Elliott P, et al. Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet. 2009; 374: 1986-1996.
62. Koskenvuo JW, Hartiala JJ, Nuutila P, et al. Twenty-fourmonth alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters. J Inherit Metab Dis. 2008; 31: 432-441.
63. Hasegawa H, Takano H, Shindo S, et al. Images in cardiovascular medicine. Transition from left ventricular hypertrophy to massive fibrosis in the cardiac variant of Fabry disease. Circulation. 2006; 113: e720-721.
64. Kovacevic-Preradovic T, Zuber M, Attenhofer Jost CH, et al. Anderson-Fabry disease: long-term echocardiographic follow- up under enzyme replacement therapy. Eur J Echocardiogr. 2008; 9: 729-735.
65. Beer M, Weidemann F, Breunig F, et al. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. Am J Cardiol. 2006; 97: 1515-1518.
66. Weidemann F, Niemann M, Breunig F, et al. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation. 2009; 119: 524-529.
67. Lidove O, West ML, Pintos-Morell G, et al. Effects of enzyme replacement therapy in Fabry disease-a comprehensive review of the medical literature. Genet Med. 2010; 12: 668-679.
68. Germain DP, Waldek S, Banikazemi M, et al. Sustained, longterm renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol. 2007; 18: 1547-1557.
69. Schiffmann R, Kopp JB, Austin HA 3rd, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001; 285: 2743-2749.
70. Vedder AC, Breunig F, Donker-Koopman WE, et al. Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol Genet Metab. 2008; 94: 319-325.
71. Ohashi T, Iizuka S, Ida H, Eto Y. Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease. Mol Genet Metab. 2008; 94: 313-318.
72. Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med. 2003; 138: 338-346.
73. Ziegler RJ, Yew NS, Li C, et al. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer. Hum Gene Ther. 1999; 10: 1667-1682.
74. Ziegler RJ, Li C, Cherry M, et al. Correction of the nonlinear dose response improves the viability of adenoviral vectors for gene therapy of Fabry disease. Hum Gene Ther. 2002; 13: 935-945.
75. Ziegler RJ, Lonning SM, Armentano D, et al. AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice. Mol Ther. 2004; 9: 231-240.
76. Przybylska M, Wu IH, Zhao H, et al. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors. J Gene Med. 2004; 6: 85-92.
77. Eng CM, Germain DP, Banikazemi M, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med. 2006; 8: 539-548.